Quality of Life with Macular Degeneration: Perceptions of Patients, Clinicians, and Community Members

Overview

Journal Br J Ophthalmol

Specialty Ophthalmology

Date 2002 Dec 19

PMID 12488253

Citations 29

Authors

J D Stein

M M Brown

G C Brown

H Hollands

S Sharma

Affiliations

Soon will be listed here.

Abstract

Background/aims: Age related macular degeneration (ARMD) is a common ophthalmological disorder that can significantly impair a patient's ability to function independently and potentially have a dramatic impact on health related quality of life. The aim of this study is to evaluate the quality of life of patients with ARMD, through the use of utility evaluation, and assess whether clinicians and healthy volunteers appreciate the impact of ARMD on health related quality of life.

Methods: A standardised questionnaire using the time-tradeoff method of utility analysis was created to assess health related quality of life. This questionnaire was distributed to 115 patients with ARMD. A similar questionnaire was distributed to 142 healthy volunteers and 62 clinicians who were asked to assume that they had ARMD. Comparisons were made among the responses from the members of the three groups.

Results: There was a significant difference in the utility scores among respondents with mild, moderate, and severe ARMD when compared to members of the general public and clinicians who were asked to assume they had each severity of ARMD. For mild ARMD the mean utility scores were 0.932, 0.960, and 0.832, for the general public, clinicians, and patients respectively (F = 21.7; p <0.001). No significant difference was found between the community members and clinicians (p <0.166); however, the patient group differed significantly from the general public (p<0.001) and clinician (p <0.001) groups. The utility scores for moderate ARMD for the general public, clinicians, and patients were 0.918, 0.877, and 0.732, respectively. (F = 34.6, p <0.001). There was no significant difference between the general public and clinicians (p <0.143); however, the patient group differed significantly compared with the general public (p <0.001) and clinician (p <0.001) groups. The utility scores for people with severe ARMD in the general public, clinician, and patient groups were 0.857, 0.821, and 0.566, respectively (F = 45.5; p <0.001). No significant difference was shown between the community members and clinicians (p <0.386); however, a significant difference was seen when comparing the patient group with the community member and clinician (p<0.001) groups.

Conclusion: Clinicians and community members may greatly underestimate the impact of mild, moderate, and severe ARMD on health related quality of life.

Citing Articles

Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration.

Gyenes A, Istvan L, Benyo F, Papp A, Resch M, Sandor N BMC Ophthalmol. 2023; 23(1):14.

PMID: 36627583 PMC: 9830890. DOI: 10.1186/s12886-022-02761-9.

Incongruent Views of Functioning between Patients and Gastroenterologists: A Mixed Methods Study.

Eiroa-Orosa F, Georghiades A, Rodriguez-Urrutia A, Accarino A Healthcare (Basel). 2023; 11(1).

PMID: 36611522 PMC: 9818837. DOI: 10.3390/healthcare11010062.

Biomarkers for Nonexudative Age-Related Macular Degeneration and Relevance for Clinical Trials: A Systematic Review.

Fang V, Gomez-Caraballo M, Lad E Mol Diagn Ther. 2021; 25(6):691-713.

PMID: 34432254 DOI: 10.1007/s40291-021-00551-5.

Opportunities to Reduce Potential Bias in Ophthalmic Cost-Utility Analysis.

Brown G, Brown M, Chaudhry I, Stein J JAMA Ophthalmol. 2021; 139(4):389-397.

PMID: 33538789 PMC: 7863010. DOI: 10.1001/jamaophthalmol.2020.6591.

Impact of Visual Impairment on the Wellbeing and Functional Disability of Patients with Glaucoma in India.

Dubey S, Bedi H, Bedi M, Matah P, Sahu J, Mukherjee S J Curr Ophthalmol. 2020; 32(1):14-18.

PMID: 32510008 PMC: 7265270. DOI: 10.1016/j.joco.2019.09.006.

References

Williams R, Brody B, Thomas R, Kaplan R, Brown S . The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998; 116(4):514-20. DOI: 10.1001/archopht.116.4.514. View

Samsa G, Matchar D, Goldstein L, Bonito A, Duncan P, Lipscomb J . Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am Heart J. 1998; 136(4 Pt 1):703-13. DOI: 10.1016/s0002-8703(98)70019-5. View

Brown M, Brown G, Sharma S, Garrett S . Evidence-based medicine, utilities, and quality of life. Curr Opin Ophthalmol. 1999; 10(3):221-6. DOI: 10.1097/00055735-199906000-00012. View

Lalonde L, Clarke A, Joseph L, Mackenzie T, Grover S . Comparing the psychometric properties of preference-based and nonpreference-based health-related quality of life in coronary heart disease. Canadian Collaborative Cardiac Assessment Group. Qual Life Res. 1999; 8(5):399-409. DOI: 10.1023/a:1008991816278. View

Brown G, Sharma S, Brown M, Garrett S . Evidence-based medicine and cost-effectiveness. J Health Care Finance. 1999; 26(2):14-23. View

Hazel C, Petre K, Armstrong R, Benson M, Frost N . Visual function and subjective quality of life compared in subjects with acquired macular disease. Invest Ophthalmol Vis Sci. 2000; 41(6):1309-15. View

Brown G, Brown M, Sharma S . Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol. 2000; 35(3):127-33. DOI: 10.1016/s0008-4182(00)80005-8. View

VanNewkirk M, Nanjan M, Wang J, Mitchell P, Taylor H, McCarty C . The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology. 2000; 107(8):1593-600. DOI: 10.1016/s0161-6420(00)00175-5. View

Brown M, Brown G, Sharma S, Kistler J, Brown H . Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001; 85(3):327-31. PMC: 1723892. DOI: 10.1136/bjo.85.3.327. View

10.

Stein J, Brown G, Brown M, Sharma S, Hollands H, STEIN H . The quality of life of patients with hypertension. J Clin Hypertens (Greenwich). 2002; 4(3):181-8. PMC: 8101809. DOI: 10.1111/j.1524-6175.2002.00970.x. View

11.

Jachuck S, BRIERLEY H, Jachuck S, Willcox P . The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract. 1982; 32(235):103-5. PMC: 1971011. View

12.

Torrance G . Measurement of health state utilities for economic appraisal. J Health Econ. 1986; 5(1):1-30. DOI: 10.1016/0167-6296(86)90020-2. View

13.

Kaplan R, Anderson J . A general health policy model: update and applications. Health Serv Res. 1988; 23(2):203-35. PMC: 1065501. View

14.

Froberg D, Kane R . Methodology for measuring health-state preferences--II: Scaling methods. J Clin Epidemiol. 1989; 42(5):459-71. DOI: 10.1016/0895-4356(89)90136-4. View

15.

Torrance G, Feeny D . Utilities and quality-adjusted life years. Int J Technol Assess Health Care. 1989; 5(4):559-75. DOI: 10.1017/s0266462300008461. View

16.

Mangione C, Phillips R, Seddon J, Lawrence M, Cook E, Dailey R . Development of the 'Activities of Daily Vision Scale'. A measure of visual functional status. Med Care. 1992; 30(12):1111-26. DOI: 10.1097/00005650-199212000-00004. View

17.

Redelmeier D, Detsky A . A clinician's guide to utility measurement. Prim Care. 1995; 22(2):271-80. View

18.

Lieberman J, dOrey F, Shekelle P, Schumacher L, Thomas B, Kilgus D . Differences between patients' and physicians' evaluations of outcome after total hip arthroplasty. J Bone Joint Surg Am. 1996; 78(6):835-8. DOI: 10.2106/00004623-199606000-00005. View

19.

Rothwell P, McDowell Z, Wong C, Dorman P . Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ. 1997; 314(7094):1580-3. PMC: 2126825. DOI: 10.1136/bmj.314.7094.1580. View

20.

Smith W, Mitchell P, Wang J . Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. Aust N Z J Ophthalmol. 1997; 25 Suppl 1:S13-5. DOI: 10.1111/j.1442-9071.1997.tb01745.x. View